Interleukin-3. Biologic effects and clinical impact.
Human interleukin-3 (IL-3) is expressed in yeast and has a specific activity of 5 x 10(7) U/mg of protein. It exerts functional and proliferative effects on multiple hematopoietic cell lineages including the neutrophil, eosinophil, basophil, monocytic, and thrombopoietic cell lines. IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) share common binding capacities on hematopoietic cells. Each of these agents has entered clinical trials. The clinical experiences with IL-3 alone and in combination with GM-CSF in a Phase I/II trial are summarized in this report.
Oster
W
W
Clinical Research Immunology/Oncology Department, Behringwerke AG, Marburg, Germany.
Frisch
J
J
Nicolay
U
U
Schulz
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001856:Bone Marrow Examination; D004341:Drug Evaluation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D012016:Reference Values
D007377:Interleukin-3; D016178:Granulocyte-Macrophage Colony-Stimulating Factor